Research record
Vemurafenib + cobimetinib
A BRAF-mutant melanoma targeted combination. It is not relevant to NRAS unless the molecular report also documents qualifying BRAF mutation.
What this is
A BRAF-mutant melanoma targeted combination. It is not relevant to NRAS unless the molecular report also documents qualifying BRAF mutation.
Why it may come up
- cannot be removed by surgery
- has spread
- BRAF V600 confirmed
What not to assume
- Do not apply to NRAS-only melanoma.
At a glance
Vemurafenib + cobimetinib
- Type
- Targeted therapy
- Mutation result
- BRAF V600
- Where
- US, EU, Unknown
- Evidence status
- Approved in listed place
- Last checked
- 2026-05-20
What we know
- NCI drug page lists BRAF/MEK drugs approved for melanoma.
What is unclear
- Country-specific label and reimbursement map remains incomplete.
Questions to ask
- Is the BRAF mutation a qualifying V600 variant?
- How does this compare with immunotherapy sequencing?
- What country label/reimbursement applies?